Optimal mobilization of autologus CD34+ cells for ASCT has been reported to improve overall survival (OS) and event-free survival in peripheral T-cell lymphoma (32), and higher graft CD34+ cell counts have been associated with better OS in patients with diffuse large B-cell lymphoma (33). This evidence concerns the gene CD34 and diffuse large B-cell lymphoma.